Eli Lilly signed a global R&D collaboration with Insilico Medicines worth up to $2.75 billion, expanding Lilly’s use of AI for oral therapeutic discovery. Under the agreement, Insilico receives an upfront payment of $115 million, with additional payments tied to development, regulatory, and commercial milestones. The partnership grants Lilly worldwide rights to develop, manufacture, and commercialize an initial portfolio of oral therapeutics in preclinical development across multiple disease areas. Beyond that first set, Lilly and Insilico will jointly pursue new programs based on targets selected by Lilly. Insilico’s approach is described as deep learning for end-to-end drug discovery, while Lilly executives said the collaboration is intended to explore novel mechanisms and speed candidate identification across indications. The deal reinforces continued biopharma appetite for AI-enabled discovery platforms, particularly where companies can pair machine learning pipelines with internal translation and regulatory execution.